What is Applied Stemcell?
Applied Stemcell operates as a high-impact contract research organization (CRO) and contract development and manufacturing organization (CDMO) dedicated to the advancement of gene and cell therapy. The company distinguishes itself through two primary technological pillars: the CRISPR/TARGATT genome editing platform and its GMP-grade induced pluripotent stem cell (iPSC) services. These capabilities allow the firm to serve as a vital partner for pharmaceutical and biotech entities seeking to navigate the complexities of therapeutic development.
In an industry defined by rapid innovation and stringent regulatory requirements, Applied Stemcell provides the essential technical infrastructure required to translate laboratory-scale research into clinical-grade applications. Its market position is bolstered by a commitment to precision medicine, enabling clients to streamline the development of novel therapeutics while maintaining high standards of quality and scalability.
How much funding has Applied Stemcell raised?
Applied Stemcell has raised a total of $25M across 5 funding rounds:
Series B
$1.9M
Series C
$2.6M
Series D
$19M
Debt
$1M
Debt
$500K
Series B (2010): $1.9M, investors not publicly disclosed
Series C (2013): $2.6M, investors not publicly disclosed
Series D (2016): $19M supported by BioSciKin, Vi-Ventures, Hermed Capital, and Ping An Ventures
Debt (2020): $1M featuring PPP
Debt (2021): $500K backed by PPP
Key Investors in Applied Stemcell
BioSciKin
BioSciKin is an open platform for life science entrepreneurs, focusing on novel therapeutics, medical devices, and mobile healthcare services through R&D-oriented incubation parks.
Vi-Ventures
A boutique investment firm specializing in TMT and healthcare technology, facilitating cross-border expansion between China, the United States, and Israel.
Hermed Capital
A private investment firm providing flexible working capital solutions and financial support to businesses, emphasizing common sense and professional service over institutional bureaucracy.
What's next for Applied Stemcell?
Looking ahead, the strategic deployment of the $500K is expected to focus on the expansion of the company's GMP-grade manufacturing facilities and the further refinement of its CRISPR-based editing capabilities. As the therapeutic landscape shifts toward more personalized and gene-centric interventions, Applied Stemcell is well-positioned to capture additional market share by providing the necessary technical scaffolding for global drug developers.
The company's growth trajectory suggests a continued emphasis on international partnerships and the scaling of its R&D-oriented incubation services. By maintaining its focus on high-impact therapeutic areas, Applied Stemcell is poised to remain a central node in the global biotechnology supply chain, driving efficiency and innovation in the development of life-saving medical treatments.
